The FDA approved Sanofi’s daily diabetes drug Toujeo Wednesday, but the new treatment does not appear to pack a profile that will pull payers or physicians away from Lantus to generic-free Toujeo.

Merck announced that two Phase 3 studies evaluating MK-1293, an investigational, follow-on biologic insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes, achieved ...

Sanofi top-lined positive late-stage clinical data today from a new basal insulin designed to help the French drugmaker defend its position in this fast-growing segment of diabetes treatment. In two ...

NEW ORLEANS--Merck & Co. won’t be the first to roll out a biosimilar version of Sanofi’s multibillion-dollar basal insulin, Lantus. But it aims to step up the competition when it does--and new data ...

Lou is a freelance journalist and content writer with a focus on the automotive world. After graduating from Coventry University (Automotive Journalism MA) in 2020, she worked in automotive e-commerce ...

Livestock equipment dealer and former Nebraskaland Days board member Bob Lantis will succeed the retiring David Fudge as the annual June festival’s executive director. Lantis, owner of RJL Enterprises ...

Lantis Laser is partnering with Axsun Technologies to upgrade its optical coherence tomography (OCT) dental system. Axsun designs integrated microelectromechanical systems (MEMs) OCT engines. The ...

Dennis “Denny” Lantis, a longtime police officer in the McHenry area, loved his tough line of work but also made friends as a skilled antique refinisher who once restored two bars for a Harvard tavern ...